Lenard Lichtenberger, PhD (CSO) has focused his research over the past 35 years on aspirin and related NSAIDs. His laboratory research, which has been supported by over $20M in grant support (mostly NIH and DoD/Army), with 150+ peer-reviewed publications and 10+ issued U.S. and worldwide patents, has culminated in the development of a new class of lipid-associated NSAIDs (PC-NSAIDs) that have reduced toxicity to the GI tract while maintaining full therapeutic activity. He co-founded PLx Pharma Inc, a company with the goal of producing this family of NSAIDs. Their first drug, Aspirin-PC, sold under the brand name Vazalore, has been approved for sale by the FDA. Dr. Lichtenberger collaborates with scientists at The University of Texas M.D. Anderson Cancer Center, Baylor College of Medicine, Oregon State University, and the American University Sciences in Long Beach CA. He recently joined J&D Pharma as our Chief Scientific Officer to manage science strategy in the development of SAL-PC formulations into products for commercial use in traumatic brain injury as well as other neuroinflammatory conditions.